IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Aggregated presentation by day and by market
Read more:
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies…
MHSRS is America’s Foremost Annual Military Healthcare Conference MHSRS is America’s Foremost Annual Military Healthcare Conference
Originally posted here:
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies...
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
CLEVELAND, June 11, 2024 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a leader in the use of peripheral nerve stimulation (PNS) to address different types of pain throughout the body, announced the publication of a review of prospective studies evaluating the impact on chronic pain following percutaneous PNS treatment. Published in Pain Management, the review identified studies evaluating PNS treatment for three primary treatment applications: low back pain, shoulder pain, and neuropathic pain. Studies included in the review all utilized treatment with short-term percutaneous PNS for up to 60 days with leads placed to target participants’ specific pain.
Continue reading here:
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing. This formalizes the binding term sheet previously announced May 10, 2024.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on June 6, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement equity grants covering an aggregate of 56,080 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 9,230 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 46,850 shares of its common stock.
Read the rest here:
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
SAN FRANCISCO, June 11, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Manher (AJ) Joshi, M.D., as Chief Medical Officer.
Continued here:
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN’s comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infections // QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts // New assays add to QIAGEN’s comprehensive portfolio for microbial research showcased at ASM Microbe conference from June 13-17
Read the original post:
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
Read the original post:
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tonix Pharmaceuticals Announces Proposed Public Offering
CHATHAM, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof). All of the securities to be sold in the offering are to be offered by Tonix. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
See the rest here:
Tonix Pharmaceuticals Announces Proposed Public Offering
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove…
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a commitment letter (the “Commitment Letter”) with Perigrove LLC and Graf Holdings (collectively the “Lender”) for a $100 million 5-year term financing with royalty-based payments (“Commitment”). The Company intends to use the funds to repay the outstanding amount of its existing senior secured loan provided by Oramed Pharmaceuticals Inc., which is approximately $85 million. The Company intends to use the rest of the funds raised, which is estimated to be $15 million, for general corporate purposes.
Read this article:
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove...